HDV biomarker study for people on BLV therapy
Part of Infections clinical trials.
This study looks at blood markers in people with hepatitis D who are already taking BLV (bulevirtide) to better understand the infection. It may help doctors learn more about how the virus changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have hepatitis D infection, with or without compensated cirrhosis (liver scarring that is still working well).
- You have started taking BLV (bulevirtide) 2 mg daily as your only treatment for hepatitis D, as recommended by recent guidelines.
- You are also taking a nucleoside analogue for hepatitis B, and your hepatitis B virus level is very low (less than 20 IU/mL) when you start BLV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing treatments for people with chronic hepatitis D, a serious liver infection. If you have antibodies to the hepatitis D virus (HDV), you may be able to join and help find better ways to manage this condition.
This study uses a mobile diary app to track symptoms and quality of life for people living with hepatitis D infection. It may help researchers better understand the patient experience.
This study looks at how well the drug bulevirtide (BLV) works over a long period for people with hepatitis D (HDV) and liver scarring that is still under control (compensated cirrhosis). It may help you if you have been taking BLV alone and want to see how your liver and health have been doing.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study looks at patient information (your health data) for adults who test positive for HDV. You may help researchers better understand HDV by allowing their team to collect and use your data.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
Hear when a new HDV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.